Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
What to Watch for in a Business Development Company - Barron's

1h barrons
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
WFCNP WFC.PRL WFC.PRJ HTGZ WFC.PRT WFC.PRR WFC.PRQ SLRC WFC.PRP WFC.PRO WFC.PRN TSLX WFC.PRY WFC.PRX SLRA WFC.PRW WFC.PRV WFC WFC.WS ARCC GBDC TCPC HTGX HTGY ARU HTGC

54
Bank ETFs Rise on the Wave of Big Releases

19h zacks
The financial sector, which accounts for around one-fifth of the S&P 500 index, is now busy with Q2 earnings releases. The going is great so far, with five big banks crushing estimates on both lines and one reporting mixed results. The backdrop should favor the banks along with the course of oil, the stance taken by the Fed and the proposed policies of Trump (read: How Financial ETFs Look After Fed Stress Test).
WFCNP C.WSA MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA BAC WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS BAC C VFH C.PRL IYG C.PRJ C.PRK C.PRG C.PRC MS.PRI C.PRPCL MS.PRK CGBBW

4
Calfrac: Wilks Brothers Push For A Sale Of The U.S. Business

21h seekingalpha
After touching C$8.0, the shares traded below C$6.0 amid sector-wide Permian concerns and refinancing drama involving Wilks Brothers.
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN CFWFF WFC.PRY WFC.PRX WFC.PRW WFC.PRV

4
V.F. Corporation (VFC) CEO Steve Rendle on Q1 2019 Results - Earnings Call Transcript

21h seekingalpha
Greetings, and welcome to the V.F. Corporation First Quarter Fiscal 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
WFC WFCNP WFC.WS MQBKY WFC.PRL WFC.PRJ MCQEF WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX MQG WFC.PRW WFC.PRV

6
Schlumberger Limited's (SLB) CEO Paal Kibsgaard on Q2 2018 Results - Earnings Call Transcript

2018-07-20 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Schlumberger earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions]. As a reminder, today's call is being recorded.
WFC WFCNP WFC.WS SLB WFC.PRL WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN SCL SLB WFC.PRY WFC.PRX WFC.PRW WFC.PRV

32
Top Research Reports for Microsoft, Novartis & Goldman Sachs

2018-07-20 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Novartis (NVS) and Goldman Sachs (GS). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
WFCNP HD NTRSP KMI.WS WFC.PRL WAFDW WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ KMI.PRA WFC.PRP KMI NTRS WFC.PRO GM.WS.A WFC.PRN GM.WS.B GM.WS.C WAFD GM WFC.PRY WFC.PRX KMR CVB WFC.PRW WFC.PRV WFC WFC.WS ROST NVS MSFT SBUX GM.WSB KMRFZ

21
News Viewer - MarketWatch

2018-07-20 marketwatch
U.S. stocks rose slightly on Friday, with technology stocks leading the day’s advance following strong results from Microsoft, one of the industry’s most closely watched bellwethers. Full Story
WFC WFCNP WFC.WS GEC GE WFC.PRL WFC.PRJ NFLX VZA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN VZ GNE WFC.PRY WFC.PRX WFC.PRW WFC.PRV

21
FBI has tape of Trump and Cohen discussing Playmate payment: N.Y. Times

2018-07-20 feeds.marketwatch
Technically speaking, the U.S. benchmarks have responded well to this week’s round of second-quarter earnings reports. On a headline basis, the S&P 500 has sustained a slight, but potentially consequential July breakout, staging a successful retest of major support (2,802). Full Story
WFC WFCNP WFC.WS GEC GE WFC.PRL WFC.PRJ NFLX VZA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN VZ GNE WFC.PRY WFC.PRX WFC.PRW WFC.PRV

4
Texas Capital's Strong Loan Growth And Spread Leverage Is A Potent Growth Cocktail

2018-07-20 seekingalpha
Exceptional asset sensitivity and loan growth are generating strong revenue and operating income growth for this Texas-based commercial lender.
WFC WFCNP WFC.WS CMA TCBI WFC.PRL TCBIL WFC.PRJ WFC.PRT WFC.PRR TCBIW WFC.PRQ WFC.PRP WFC.PRO TCBIP WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV

63
Bank Stock Roundup: Q2 Earnings Season Unfolds, JPMorgan, BofA & Citi Top Estimates

2018-07-20 zacks
Most banks that reported second-quarter 2018 results this week managed to record bottom-line improvement on the back of rising rates, lower provisions and improved trading activities. This also led to positive price movement for most bank stocks over the last five trading days. In addition to the benefits from higher interest rates, banks’ results mirrored a marginal upswing in loans. Moreover, the results display eased margin pressure.
WFCNP HBANN ZIONW HBANO HBANP WFC.PRL WFC.PRJ ZB.PRF FITBI ZB.PRA PB BAC USB WFC.PRT ZBK WFC.PRR ZION WFC.PRQ WFC.PRP WFC.PRO WFC.PRN BKU WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS BAC C HBAN ZB.PRG ZB.PRH FITB CFR ZIONZ

50
Top Analyst Upgrades and Downgrades: AEP, Facebook, Microsoft, PayPal, Philip Morris, Spotify, Under Armour and More

2018-07-20 247wallst
Stocks were indicated lower on Friday on more China woes, but it’s been a choppy time of late. The investing community has had less faith and has seen lower rewards from buying the dips in 2018 than in prior years. Many of those same investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and into 2019 and beyond.
WFCNP PM FB GLMD UAA MS.PRE WFC.PRL MS.PRF PYPL WFC.PRJ MS.PRG SKX MS.PRA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO SPOT WFC.PRN AEP WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS AEP.PRA YUMC ISRG ETR UA SIX MS.PRI MS.PRK FDC RARX TRI MSFT ESRX

9
Bear of the Day: Keurig Dr Pepper, Inc. (KDP)

2018-07-20 zacks
Keurig Dr Pepper, Inc (KDP - Free Report) , a Zacks Rank #5 (Strong Sell), is a leading coffee and beverage company in North America, with annual revenue in excess of $11 billion. KDP holds leadership positions in soft drinks, specialty coffee and tea, water, juice and juice drinks and mixers, and markets the #1 single serve coffee brewing system in the U.S. The Company maintains an unrivaled distribution system that enables its portfolio of more than 125 owned, licensed and partner brands to be available nearly everywhere people shop and consume beverages.
WFC WFCNP WFC.WS KDP WFC.PRL WFC.PRJ WFC.PRT WFC.PRR PRMW WFC.PRQ WFC.PRP GTT WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW TUP GMCR WFC.PRV

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 949746804